This Monster Dividend Stock Isn't Done Growing
Johnson & Johnson (NYSE: JNJ) is in the midst of a transition. The company is spinning off its consumer health business next year, allowing the remaining entity to focus more on growth initiatives. For investors, that can make the dividend stock an attractive investment since its consumer health business was never a fast-growing segment of its operations.
One way the business can accelerate its plans for growth is via acquisitions, and Johnson & Johnson has been busy on that front of late.
Horizon Therapeutics Public (NASDAQ: HZNP), a healthcare business that makes medicines to treat autoimmune and inflammatory diseases, issued a press release on Nov. 29 stating that it is in "preliminary discussions" regarding a potential acquisition of its business. It lists multiple potential acquirers, including Amgen, Sanofi, and Janssen (a company that's part of Johnson & Johnson).
Source Fool.com
